Besides, FDA recommended Pembrolizumab in combination with platinum and fluorouracil for all advanced HNSCC patients, and as monotherapy for patients whose PD-L1 expression Combined Positive Score (CPS) is ≥1% (16). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.